Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy

Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that binds to free IL-5. It induces bone marrow eosinophil maturation arrest and decreases eosinophil progenitors and subsequent maturation in the blood and bronchial mucosa. Its use has been extensively studied in severe eosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Faverio, Paola, Bonaiti, Giulia, Bini, Francesco, Vaghi, Adriano, Pesci, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292233/
https://www.ncbi.nlm.nih.gov/pubmed/30573961
http://dx.doi.org/10.2147/TCRM.S159949

Ejemplares similares

Ejemplares similares